Therapeutic strategies for local recurrent malignant glioma

Current Treatment Options in Oncology

Volumn 5, Issue 6, 2004, Pages 491-497

  Sills Jr , Allen K ^a   Duntsch, Chris ^b   Weimar, Jay ^b  

^a UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ANTICONVULSIVE AGENT; ANTIFUNGAL AGENT; CANCER ANTIBODY; CARMUSTINE; CORTICOSTEROID; DIPHTHERIA TOXIN; INTERLEUKIN 13; LOMUSTINE; METHYLPHENIDATE; MODAFINIL; NITROSOUREA; PROCARBAZINE; PSEUDOMONAS EXOTOXIN; STEROID; TEMOZOLOMIDE; TRANSFERRIN RECEPTOR; TUMOR VACCINE; VINCRISTINE;

ADJUVANT CHEMOTHERAPY; ADOPTIVE IMMUNOTHERAPY; BRAIN INFARCTION; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER SURGERY; CLINICAL TRIAL; COGNITIVE DEFECT; DENDRITIC CELL; DIAGNOSTIC IMAGING; DRUG TARGETING; GLIOBLASTOMA; HISTOLOGY; HUMAN; MOOD DISORDER; OPPORTUNISTIC INFECTION; PNEUMOCYSTIS PNEUMONIA; QUALITY OF LIFE; RECURRENT CANCER; REVIEW; SEIZURE; SURVIVAL RATE; THERMODYNAMICS; TREATMENT OUTCOME;

EID: 9944234956     PISSN: 15272729     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11864-004-0037-z     Document Type: Review

References (21)

1. Lee SW, Fraass BA, Marsh LH, et al.: Patterns of failure following high-dose 3-D conformal radiotherapy for high-grade astrocytomas: a quantitative dosimetric study. Int J Radiat Oncol Biol Phys 1999, 43:79-88.
2. Lacroix M, Abi-Said D, Fourney DR, et al.: A multivariate analysis of 416 patients with glioblastoma multiforme: prognosis, extent of resection, and survival. J Neurosurg. 2001 95(2):190-8.
3. Albert FK, Forsting M, Sartor K, et al.: Early postoperative magnetic resonance imaging after resection of malignant glioma: objective evaluation of residual tumor and its influence on regrowth and prognosis. Neurosurgery 1994, 34:45-60; discussion 60-61.
4. Curin WJ, Scott CB, Horton J, et al.: Recursive partitioning analysis of prognostic factors in three radiation therapy oncology group malignant glioma trials. J Natl Cancer Inst 1993, 85:704-710.
5. Shaw E, Scott C, Souhami L, et al.: Single-dose radiosurgical treatment of recurrent previously irradiated primary brain tumor and bone metastases: final report of Radiation Therapy Oncology Group May 05. Int J Radiat Oncol Biol Phys 2000, 47: 91-298.
6. Halligan JB, Stelzer KJ, Rostomily RC, et al.: Operations in permanent low activity 125 I brachytherapy for recurrent high-grade astrocytomas. Int J Radiat Oncol Biol Phys 1996, 35:541-547.
7. Shrieve DC, Alexander E, Wen PY, et al.: Comparison of stereotactic radiosurgery and brachytherapy in the treatment of glioblastoma multiforme. Neurosurgery 1995, 36:275-284.
8. Gaspar LE, Zamorano LJ, Shamsa F, et al.: Permanent 125 iodine implants for recurrent malignant gliomas. Int J Radiat Oncol Biol Phys 1999, 43:977-982.
9. Tatter SB, Shaw EG, Rosenblum ML, et al.: An inflatable balloon catheter and liquid 125 I radiation source (GliaSite Radiation Therapy System) for treatment of recurrent malignant glioma: multicenter safety and feasibility trial. J Neurosurg 2003, 2:297-303.
10. Sanan A: Retrospective multicenter data: recurrent malignant gliomas. Paper presented at the 95th Annual Meeting of the American Association for Cancer Research. Orlando, Florida; March 27-31, 2004.
11. Walker MD, Green SV, Bial TP, et al.: Randomized comparison of radiotherapy in nitrosoureas for the treatment of malignant glioma after surgery. N Engl J Med 1980, 4:1323-1329.
12. Medical Research Council Brain Tumor Working Party: Randomized trial of procarbazine, lomustine, and vincristine in the adjuvant treatment of high-grade astrocytoma. J Clin Oncol 2001, 19:509-518.
13. Stupp R, Mason WP, Van Den Bent MJ, et al.: Concomitant and adjuvant temozolomide (TMZ) and radiotherapy (RT) for newly diagnosed glioblastoma multiforme (GBM). American Society of Clinical Oncology annual meeting proceedings, 2004 [abstract]. J Clin Oncol 2004: 22(Suppl 2):14S.
14. Combs SE, Gutwein S, Schulz-Ertner D, et al.: Temozolomide combined with radiation as first line treatment in primary glioblastoma multiforme: phase I/II study [abstract]. Proceedings of the American Society for Clinical Oncology. J Clin Oncol 2004, 22(Suppl 14):1531.
15. Valtonen S, Timonen U, Toivanen P, et al.: interstitial chemotherapy with cremestine-loaded polymers for high-grade gliomas: a randomized double-blind study. Neurosurgery 1997, 41:44-48.
16. Subach BR, Witham TF, Kondziolka D, et al.: Morbidity and survival after 1, 3-bis (2-chloroethyl)-1 nitrosourea wafer implantation for recurrent glioblastoma: a retrospective case-matched cohort series. Neurosurgery 1999, 45:17-22.
17. Weaver M, Laske DW: Transferrin receptor ligand-targeted toxin conjugate (Tf-CRM107) for therapy of malignant gliomas. J Neurooncol 2003, 65:3-13.
18. NeoPharm and Collaborators: New IL13-PE3AQQR clinical data in brain cancer. Press release presented by NeoPharm Corporation June 3, 2003.
19. Wheeler CJ, Das A, Liu G, et al.: Clinical responsiveness of glioblastoma multiforme to chemotherapy after vaccination. Clin Cancer Res 2004, 10:5316-5326.
20. Glantz MJ, Cole BF, Forsythe PA, et al.: Practice parameter: anticonvulsaut prophylaxis in patients with newly diagnosed brain tumors. Report of the quality standard subcommittee of the American Academy of Neurology. Neurology 2000, 54:18186-1893.
21. Villikka K, Kivisto KT, Maenpa AH, et al.: Cytochrome P450-inducing antiepileptics increase the clearance of vincristine in patients with brain tumors. Clin Pharmacol Ther 1999, 66:589-593.